JHH and JHBMC | Discharge Guidelines for COVID Positive Patients Still on COVID Isolation

JHSOM Dept Med, JHH/JHBMC Ambulatory Incident Command, JHH/JHBMC HEIC

Last updated August 4, 2020 at 3:50 PM EST

Many, but not all, patients can be discharged while still on COVID isolation. This document provides guidance for the patient categories listed below. These guidelines may be updated frequently. Please refer to the Hospital Epidemiology and Infection Control (HEIC) website for the most recent version.

Patients Discharging to a Private Residence

Repeat inpatient or outpatient COVID testing is not needed for patients who are being discharged to a private residence.

1. Patients who have a PCP with whom they can readily follow-up

   a. Instruct them to follow-up with their PCP (likely by phone or video) within 2-5 days.

   b. In the After Visit Summary, include the following documents:
      i. Krames Discharge Instructions:
         http://johnshopkinsibportal.staywellsolutionsonline.com/Search/22,1292
      ii. Krames COVID-19 What is Social Distancing and Self Quarantine?:
         http://johnshopkinsibportal.staywellsolutionsonline.com/Search/22,1307

   c. Uncomplicated patients* can discontinue self-isolation when ALL THREE of the clinical criteria below are met. We recommend including these three criteria in the After Visit Summary as well. (See section 3 regarding criteria for complicated patients who need to return in person for medical care.)
      i. Afebrile for 24 hours without the use of fever-reducing medications
      ii. Improvement in respiratory symptoms (e.g., cough, shortness of breath)
      iii. At least 10 days have passed since the first positive COVID-19 test was obtained.

   If an uncomplicated patient* did not have symptoms, they can discontinue self-isolation 10 days after the first positive COVID-19 test was obtained if they remain asymptomatic.

   d. Please note that some patients eligible for discontinuing outpatient COVID-19 isolation by the above criteria may achieve these criteria while still an inpatient. If this is the case, they do not need any special isolation at the time of discharge (will not need the isolation and quarantine instructions in 1b.) and should

<table>
<thead>
<tr>
<th>Definitions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Complicated Patients or Group Care Settings</td>
<td>Patients who required ICU care during their hospitalization, are severely immunocompromised* or are pregnant or less than 2 weeks post-partum. Patients who do not meet these criteria are considered uncomplicated patient cases. Group care settings include inpatient rehabilitation, psychiatry facilities or are receiving dialysis.</td>
</tr>
<tr>
<td>Uncomplicated Patients</td>
<td>Patients that do not fall into any of the groups above.</td>
</tr>
</tbody>
</table>

*Severely immunocompromised patients: The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications, click here.
simply return to the standard social distancing polices relevant to the general population when they leave the hospital.

e. Suggest patients ask their PCP to discuss when they meet the three criteria in c. above.

f. PCPs should be the ordering providers for home health needs (e.g., oxygen, durable medical equipment, nursing visits), and patients in established ambulatory substance abuse programs should plan to continue in those programs. (Please make every effort to work with case managers to ensure these links are confirmed prior to discharge).

g. Provide the patient phone line number — 410-955-9322 — for the Hopkins COVID Ambulatory Response Team (CART) that patients can call if they are unable to connect with their PCP.

2. Patients who do NOT have a PCP with whom they can readily follow-up

a. The discharging team should call the COVID Ambulatory Response Team (CART) scheduling number (410-614-0121; this is not a number for patients) to initiate CART follow-up.

b. In the After Visit Summary, include the following documents:

c. Uncomplicated patients* can discontinue self-isolation when ALL THREE of the clinical criteria below are met. We recommend including these three criteria in the After Visit Summary as well. (See section 3 regarding criteria for complicated patients who need to return in person for medical care.)
   i. Afebrile for 24 hours without the use of fever-reducing medications
   ii. Improvement in respiratory symptoms (e.g., cough, shortness of breath)
   iii. At least 10 days have passed since the first positive COVID-19 test was obtained.

d. If an uncomplicated patient* did not have symptoms they can discontinue self-isolation 10 days after the first positive COVID-19 test was drawn.

e. Please note that some patients eligible for discontinuing outpatient COVID-19 isolation by the above criteria may achieve these criteria while still an inpatient. If this is the case, they do not need any special isolation at the time of discharge (will not need the isolation and quarantine instructions in 1b.) and should simply return to the standard social distancing polices relevant to the general population when they leave the hospital. Points f – i below will not apply in these cases.

f. Instruct the patient that the CART will reach out to them for a video or telephone visit within 2 days with a provider who will evaluate symptoms and can discuss when they meet the three criteria above.

---

<table>
<thead>
<tr>
<th>Complicated Patients or Group Care Settings</th>
<th>Patients who required ICU care during their hospitalization, are severely immunocompromised* or are pregnant or less than 2 weeks post-partum. Patients who do not meet these criteria are considered uncomplicated patient cases. Group care settings include inpatient rehabilitation, psychiatry facilities or are receiving dialysis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncomplicated Patients</td>
<td>Patients that do not fall into any of the groups above.</td>
</tr>
</tbody>
</table>

*Severely immunocompromised patients: The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications, click here.
g. Provide the patient with the **CART patient phone number for questions, 410-955-9322.**

h. **FOR JHH ONLY:**
   i. If the patient has **home health needs** (e.g. oxygen, durable medical equipment, nursing visits), ask your case manager to contact the After Care Clinic (410-955-0545 or AfterCareClinic@exchange.johnshopkins.edu) where staff will serve as the ordering providers.
   ii. If the patient needs to **start opioid replacement therapy**, refer them for initial management by the After Care Clinic as outlined in the JHH COVID-19 Inpatient/Emergency Office Based Opioid Treatment Algorithm (see **Appendix**) and plan to provide a 7 day supply of buprenorphine as described therein.

   i. **FOR BAYVIEW ONLY:**
      i. If the patient has **home health needs** (e.g. oxygen, durable medical equipment, nursing visits), ask your case manager to contact Heather Agee via Staff Message with the patient’s information.
      ii. If the patient needs to **start opioid replacement therapy**, contact the BV301 practice triage nurse at 0-1483 or 0-1429 where Heather Agee or another provider can provide suboxone via telemedicine.

   3. **Complicated patients** who are also expected to return for **in-person hospital or clinic appointments, procedures, or tests**

   **Complicated patients** may shed COVID for longer periods of time. After 20 or more days since the first positive COVID-19 test, complicated patients who have no new symptoms suggestive of COVID-19 infection, but who require in-person visits/procedures/tests that cannot be performed through telemedicine or home care can be seen in regular clinic space under the same precautions as non-COVID-19 infected patients.

   Prior to 20 days since first positive COVID-19 test, complicated patients who require in-person visits/procedures/tests that cannot be performed through telemedicine or home care, **need to be seen in an area that accommodates COVID-19 positive patients.** (see criteria under “Patients Discharging to Institutional Settings” below). They do not require re-testing. A positive or negative result will not alter this protocol. The visit(s) should be coordinated with HEIC. Complicated patients who do NOT need to return in-person within 20 days should follow the guidelines in 1c. above however, it would be reasonable to continue home isolation for 20 days rather than only 10.

**Patients Experiencing Homelessness Who are Being Discharged to the Outpatient Setting**

Note that patients who do have a home should return there. The services below cannot be used for people who have a home but wish to stay away for fear of transmitting COVID or other reasons

1. **Patients actively engaged in care at Baltimore Healthcare for the Homeless** (this can be determined by asking patients, but **must be confirmed by calling Healthcare for the Homeless** at 443-703-1295, staffed M-F 8a – 4:30p).

<table>
<thead>
<tr>
<th><strong>Definitions</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Complicated Patients or Group Care Settings</strong></td>
<td>Patients who required ICU care during their hospitalization, are severely immunocompromised* or are pregnant or less than 2 weeks post-partum. Patients who do not meet these criteria are considered uncomplicated patient cases. Group care settings include inpatient rehabilitation, psychiatry facilities or are receiving dialysis.</td>
</tr>
<tr>
<td><strong>Uncomplicated Patients</strong></td>
<td>Patients that do not fall into any of the groups above.</td>
</tr>
</tbody>
</table>

*Severely immunocompromised patients: The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications, click here.
a. Ask your case manager to call the Baltimore Health Department to arrange housing (likely in a hotel) and transportation for a patient on COVID isolation.

b. Ask your case manager to establish follow-up with Healthcare for the Homeless who will provide post-discharge care including any home care services and/or buprenorphine.

c. If possible, reach out to the Healthcare for the Homeless provider to convey case details including when the patient may be projected to come off COVID isolation (see f. below)

d. If there is a delay in housing or in confirming with Healthcare for the Homeless, or if the patient is a complicated patient*, please discuss with discharge coordinator as to requirements from Healthcare for the Homeless, in conjunction with hospital epidemiology and infection control, (see section below for patients discharging to institutional settings).

e. Note that which home health services are available in the hotel setting may vary by the hotel and by the patient (e.g. is the patient or his/her partner able to administer IV antibiotics, physical therapy, etc.). Plans will have to be individualized for each patient in discussions with case management and Healthcare for the Homeless.

f. In the After Visit Summary, include
   i. The follow-up plan that has been worked out with Healthcare for the Homeless
   ii. The following documents
      3. The three criteria below that are used to discontinue COVID-19 isolation for uncomplicated patients*
         a. Afebrile for 24 hours without the use of fever-reducing medications
         b. Improvement in respiratory symptoms (e.g., cough, shortness of breath)
         c. At least 10 days have passed since the first positive COVID-19 test was obtained.


   a. Ask your case manager to call the Baltimore Health Department to arrange housing (likely in a hotel) and transportation for a patient on COVID isolation.
   b. This housing need will continue until they meet requirements for discontinuation from COVID-19 isolation precautions.
   c. Uncomplicated patients* can discontinue self-isolation when ALL THREE of the following clinical criteria are met. (See below regarding criteria for complicated patients who need to return in person for medical care.) We recommend including these three criteria in the After Visit Summary as well.

   | Definitions |
   |------------------|--------------------------------------------------|
   | Complicated Patients or Group Care Settings | Patients who required ICU care during their hospitalization, are severely immunocompromised* or are pregnant or less than 2 weeks post-partum. Patients who do not meet these criteria are considered uncomplicated patient cases. Group care settings include inpatient rehabilitation, psychiatry facilities or are receiving dialysis. |
   | Uncomplicated Patients | Patients that do not fall into any of the groups above. |

*Severely immunocompromised patients: The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications, click here.
Patients Discharging to Institutional Settings

Relevant patients include those who will be returning to long-term care and assisted living facilities, patients who originated from a private residence but need to discharge to a skilled nursing facility setting, and patients discharging to

<table>
<thead>
<tr>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Complicated Patients or Group Care Settings</strong></td>
</tr>
<tr>
<td><strong>Uncomplicated Patients</strong></td>
</tr>
</tbody>
</table>

\(^1\)Severely immunocompromised patients: The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications, click here.
inpatient rehabilitation facilities, skilled nursing facilities for short-term needs (i.e. parenteral antibiotics), group homes, inpatient substance abuse centers, or other institutional settings.

Requirements for these sets of patients vary depending on the receiving institution, and have been changing in recent weeks. The most important clinical guidance is to work closely with your unit’s case manager (and physical/occupational therapists as relevant) starting early in the hospitalization to identify the likely destination and what the requirements will be.

1. Institutions that can accept patients who are still on COVID-19 isolation (as identified by the case manager)
   a. This should include most patients who were previously residing in a long-term care or assisted living facility and will be returning to that facility and may include other facilities and patients on a case by case basis.

2. Institutions that CANNOT accept patients who are still on COVID-19 isolation (as identified by the case manager). Discuss with case manager and infection control the requirements for transferring institution.

Patients Who Will Attend Ambulatory Hemodialysis Centers

- Many COVID-19 positive hemodialysis patients can receive outpatient dialysis in COVID-19 positive dialysis centers in the Baltimore area.
  o The inpatient nephrology team, together with the social workers, will arrange for slots in an appropriate COVID-19 positive center and will ensure patients have transport arrangements from their homes to the dialysis center.
  o If there are anticipated delays, please discuss with nephrology and infection control whether to institute the test-based strategy (see above regarding patients discharging to institutional settings) to attempt to remove from COVID-19 isolation prior to discharge. This may depend on the outpatient dialysis center’s guidelines for discontinuing COVID-19 isolation, which may be different than our strategy.

- For patients that nephrology and social work determine cannot receive outpatient dialysis in a COVID-19 positive center (because live outside the Baltimore area or other reasons), discuss with nephrology and with infection control on a case by case basis whether they can transfer to a new center and/or what strategy is required to make them safe for their dialysis center.

- Depending on whether patients discharge to a private residence, to a city-sponsored housing facility (for persons experiencing homelessness), or to an institutional facility, the guidelines for their place of residence (see categories above) will still apply irrespective of their hemodialysis isolation status.

* Definitions

| Complicated Patients or Group Care Settings | Patients who required ICU care during their hospitalization, are severely immunocompromised and/or are pregnant or less than 2 weeks post-partum. Patients who do not meet these criteria are considered uncomplicated patient cases. Group care settings include inpatient rehabilitation, psychiatry facilities or are receiving dialysis. |
| Uncomplicated Patients | Patients that do not fall into any of the groups above. |

*Severely immunocompromised patients: The degree of immunocompromise for the patient is ultimately determined by the treating provider. Conditions include but are not limited to active chemotherapy, active hematologic malignancy, solid organ or bone marrow transplant recipient, untreated HIV infection with CD4 T lymphocyte count < 200, primary or acquired severe immunodeficiency disorder, treatment with high-dose prednisone or the equivalent, or treatment with other immunocompromising agents. For a list of high-risk immunosuppression medications, click here.*

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

These policies and all information are provided for informational purposes only and are intended to supplement, but not overrule, the judgment of a qualified medical professional. All information is meant for use by clinicians, not the general public, and does not constitute provision of medical advice nor a statement of the standard of care. This educational information is being made available in the context of the public health emergency related to the coronavirus (COVID-19) and has not been subjected to review, investigation, or testing that typically would be performed in a non-emergent situation. This information is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment and should be adapted to the patient’s specific needs, available resources, and any other unique circumstances. Neither The Johns Hopkins University nor The Johns Hopkins Health System Corporation or its affiliates, or any of their employees (collectively, “Johns Hopkins”) makes any representations or warranties, express or implied, with respect to the information provided herein or to its use. Johns Hopkins shall not be liable for any loss, damage, or claim incurred from reliance on the information provided.
Appendix: Johns Hopkins Hospital after Care Clinic Algorithm for COVID Patients on Opioid Therapy

COVID-19 Inpatient/Emergency Office Based Opioid Treatment (OBOT) Algorithm

Prepared by The Johns Hopkins After Care Clinic; Updated 3/05/2020

1. **Patient on Stable Dose**
   - **VERIFY** Is patient able to obtain an extended prescription for buprenorphine/naloxone from their current program?
   - **ASK** Does patient have working phone number?
   - **OBTAIN** Urinary and Hair Drug of Abuse screen
   - **WRITE** One week supply (verify dose in OBOT if possible)
     - Include X number in RX comments
     - Naloxone Intranasal
   - **COUNSEL** (Optional withdrawal钄 Use of naloxone)
   - **REFER** to Peer Recovery Counselor

2. **NOTIFY ACC**
   - Epic Staff message to Rosalyn Stewart, MD
   - Email ACC @ aftercareclinic@exchange.johns Hopkins.edu

3. **New Start**
   - **ASK** Has patient used methadone in the last 72 hours?
   - **HOME INDUCTION**
     - SuboxoneRx 8 mg SL or buprenorphine 8 mg SL
     - Naloxone Intranasal
   - **COUNSEL** Must wait 72 hours after last dose of methadone to start bup
     - **REPEAT** dose with buprenorphine 2 mg SL if COWS <4 or asymptomatic
     - **REPEAT** dose with buprenorphine 4 mg SL if COWS >4 or Max dose of 12 mg
   - **WRITE** Over-week supply of effective dose administered, BD
     - SuboxoneRx 4 mg SL x 8 and Naloxone Intranasal

---

**Appendix: Johns Hopkins Hospital after Care Clinic Algorithm for COVID Patients on Opioid Therapy**

- **PRECIPITATED WITHDRAWAL**
  - Buprenorphine is a partial mu agonist with very high affinity for mu opioid receptors and can displace full opioid agonists.
  - Administer buprenorphine 0.8-1.2 mg SL after last opioid use and COWS=4 to avoid treatment of symptoms of opioid withdrawal.

- **HOME INDUCTION**
  - SuboxoneRx 8 mg SL or buprenorphine 8 mg SL
  - Naloxone Intranasal

- **COUNSEL** Must wait 72 hours after last dose of methadone to start buprenorphine
  - Use of naloxone

- **Provide Instructions**
  - Day 1: Place 4mg Suboxone under the tongue, allow it to fully dissolve and refrain from drinking/eating for at least 20 minutes
  - Wait 1-3 hours. If the patient still feels unwell, take an additional 4mg Suboxone dose
  - Day 2: If the patient required 4mg on day 1, on day 2 begin 4mg BD. If the patient required 8mg on day 1, on day 2 begin 8mg BD
  - Follow up in 1 week

- **OTHER CONSIDERATIONS**
  - Pregnancy
  - Buprenorphine
  - Women with history of substance abuse
  - Women on OCPs/estrogen replacement therapy

---

These policies and all information are provided for informational purposes only and are intended to supplement, not overrule, the judgment of a qualified medical professional. All information is meant for use by clinicians, not the general public, and does not constitute provision of medical advice nor a statement of the standard of care. This educational information is being made available in the context of the public health emergency related to the coronavirus (COVID-19) and has not been subjected to review, investigation, or testing that typically would be performed in a non-emergent situation. This information is not meant to be complete, exhaustive, or a substitute for medical professional advice, diagnosis, or treatment and should be adapted to the patient's specific needs, available resources, and any other unique circumstances. Neither The Johns Hopkins University nor The Johns Hopkins Health System Corporation or its affiliates, or any of its employees (collectively, “Johns Hopkins”) makes any representations or warranties, express or implied, with respect to the information provided herein or to its use. Johns Hopkins shall not be liable for any loss, damage, or claim incurred from reliance on the information provided.